What is EnGen Bio?
EnGen Bio operates as an independent pharmaceutical entity dedicated to the development of a universal influenza vaccine. By targeting a novel epitope on the M1 matrix protein of the Type A influenza virus, the company aims to provide long-lasting, broadly neutralizing antibody responses. This scientific focus positions EnGen Bio at the forefront of pandemic preparedness, supported by a robust foundation of nine patents. The company's strategic alignment with global health organizations, including the National Institutes of Health and the Bill and Melinda Gates Foundation, highlights its role in addressing critical unmet needs in global public health.
How much funding has EnGen Bio raised?
EnGen Bio has raised a total of $41K across 1 funding round:
Debt
$41K
Debt (2021): $41K with participation from PPP
Key Investors in EnGen Bio
PPP
Public-Private Partnership
What's next for EnGen Bio?
With the recent influx of capital, EnGen Bio is poised to accelerate its vaccine development program, moving closer to clinical validation. The company's roadmap involves leveraging its unique epitope-targeting technology to navigate the complexities of late-stage pharmaceutical development. By focusing on the scalability of its M1 matrix protein research, EnGen Bio intends to capture significant market share within the global vaccine sector. Future milestones will likely center on expanding human trials and solidifying manufacturing partnerships to ensure the commercial viability of its long-term immunity solution.
See full EnGen Bio company page
